New targeted pill hopes to tackle tough leukemias
NCT ID NCT07270770
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an oral drug called BY002 in 18 adults with relapsed or refractory acute leukemia that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink or control the cancer. Participants take BY002 capsules daily in 28-day cycles until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BY002 (menin inhibitor)
- What this could lead to
- If successful, this could lead to a new targeted treatment option for patients with certain types of acute leukemia who have run out of standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. The drug may cause serious side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?